Abstract
Background:
A new mechanism of action in the form of sodium-glucose co-transporter-(SGLT-)2 inhibitors will be available shortly for the treatment of type 2 diabetic patients.
Method:
Overview.
Results and conclusions:
Fasting and postprandial blood glucose and HbA(1c) concentrations are indirectly reduced by the inhibition of glucose reabsorption and increased glycosuria. SGLT-2 inhibitors also have a positive impact on body weight and blood pressure of type 2 diabetics. In the available registration trials conducted to date, the SGLT-2 inhibitors appeared overall as a safe class of drugs. The clinical importance of an increased incidence of genital infections--in particular in special patientpopulations--requires further clarification. Long-term trials are currently underway to verify safety and in particular cardiovascular effects of this drug class.
MeSH terms
-
Benzhydryl Compounds / adverse effects
-
Benzhydryl Compounds / therapeutic use
-
Canagliflozin
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / physiopathology
-
Drug Therapy, Combination
-
Follow-Up Studies
-
Glipizide / adverse effects
-
Glipizide / therapeutic use
-
Glucosides / adverse effects
-
Glucosides / therapeutic use
-
Glycosuria / drug therapy*
-
Glycosuria / physiopathology
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Kidney Tubules, Proximal / drug effects
-
Kidney Tubules, Proximal / physiopathology
-
Sodium-Glucose Transporter 2 / physiology
-
Sodium-Glucose Transporter 2 Inhibitors*
-
Thiophenes / adverse effects
-
Thiophenes / therapeutic use
Substances
-
Benzhydryl Compounds
-
Glucosides
-
Hypoglycemic Agents
-
SLC5A2 protein, human
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
Thiophenes
-
Canagliflozin
-
dapagliflozin
-
empagliflozin
-
Glipizide